tetano
Editor, Senior Moderator
J Diabetes Investig
. 2022 Jan 27.
doi: 10.1111/jdi.13757. Online ahead of print.
Newly developed type 1 diabetes after COVID-19 vaccination: A case report
Hironobu Sasaki[SUP] 1 2 [/SUP], Arata Itoh[SUP] 1 [/SUP], Yasuhiro Watanabe[SUP] 1 [/SUP], Yuya Nakajima[SUP] 1 [/SUP], Yoshifumi Saisho[SUP] 1 [/SUP], Junichiro Irie[SUP] 1 [/SUP], Shu Meguro[SUP] 1 [/SUP], Hiroshi Itoh[SUP] 1 [/SUP]
Affiliations
Abstract
The vaccine for the coronavirus disease 2019 (COVID-19) has been reported to potentially develop or worsen diabetes. A 73-year-old Japanese woman received 2 doses of Moderna COVID-19 vaccine. Four-weeks after the second vaccination, her glycemic control began to deteriorate and 8 weeks after the second vaccination, the patient was diagnosed with new-onset type 1 diabetes that was strongly positive for autoantibodies and showed a disease-susceptible HLA haplotype, DRB1*04:05:01-DQB1*04:01:01. The glucagon stimulation test suggested an insulin-dependent state and induction of intensive insulin therapy made her fair glycemic control. The duration from the COVID-19 vaccination to the development of type 1 diabetes is relatively longer than to the onset or exacerbation of type 2 diabetes as previously reported, suggesting the complicated immunological mechanisms for the destruction of β-cells associated with the vaccination. In recipients with the disease-susceptible haplotypes, it should be cautious about autoimmune responses during several months after the vaccination.
Keywords: COVID-19; Type 1 diabetes; Vaccine.
. 2022 Jan 27.
doi: 10.1111/jdi.13757. Online ahead of print.
Newly developed type 1 diabetes after COVID-19 vaccination: A case report
Hironobu Sasaki[SUP] 1 2 [/SUP], Arata Itoh[SUP] 1 [/SUP], Yasuhiro Watanabe[SUP] 1 [/SUP], Yuya Nakajima[SUP] 1 [/SUP], Yoshifumi Saisho[SUP] 1 [/SUP], Junichiro Irie[SUP] 1 [/SUP], Shu Meguro[SUP] 1 [/SUP], Hiroshi Itoh[SUP] 1 [/SUP]
Affiliations
- PMID: 35088548
- DOI: 10.1111/jdi.13757
Abstract
The vaccine for the coronavirus disease 2019 (COVID-19) has been reported to potentially develop or worsen diabetes. A 73-year-old Japanese woman received 2 doses of Moderna COVID-19 vaccine. Four-weeks after the second vaccination, her glycemic control began to deteriorate and 8 weeks after the second vaccination, the patient was diagnosed with new-onset type 1 diabetes that was strongly positive for autoantibodies and showed a disease-susceptible HLA haplotype, DRB1*04:05:01-DQB1*04:01:01. The glucagon stimulation test suggested an insulin-dependent state and induction of intensive insulin therapy made her fair glycemic control. The duration from the COVID-19 vaccination to the development of type 1 diabetes is relatively longer than to the onset or exacerbation of type 2 diabetes as previously reported, suggesting the complicated immunological mechanisms for the destruction of β-cells associated with the vaccination. In recipients with the disease-susceptible haplotypes, it should be cautious about autoimmune responses during several months after the vaccination.
Keywords: COVID-19; Type 1 diabetes; Vaccine.